RAC · ASX

Race Oncology Ltd. (ASX:RAC)

AU$1.59

 0.01 (0.633%)
ASX:Live
11/10/2024 04:10:03 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAC Overview

RAC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RAC

Website

Race Oncology Ltd.

Telephone

61.2.8051.3043

Address

Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000

Description

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$262.46M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.64 - 2.09

Trade Value (12mth)

AU$51,390.00

1 week

-6.51%

1 month

-2.77%

YTD

85.88%

1 year

91.52%

All time high

4.23

Key Fundamentals

EPS 3 yr Growth

73.60%

EBITDA Margin

N/A

Operating Cashflow

-$10m

Free Cash Flow Return

-43.60%

ROIC

-63.10%

Interest Coverage

N/A

Quick Ratio

9.30

Other Data

Shares on Issue (Fully Dilluted)

165m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAC Announcements

Latest Announcements

Date Announcements

07 October 24

Date of AGM & Closing Date for Director Nominations

×

Date of AGM & Closing Date for Director Nominations

03 October 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

02 October 24

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

26 September 24

E&P Conference Presentation

×

E&P Conference Presentation

26 September 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

18 September 24

HealthInvest 2024 Investor Presentation

×

HealthInvest 2024 Investor Presentation

13 September 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

05 September 24

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

05 September 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

02 September 24

Race Oncology Board Renewal Update

×

Race Oncology Board Renewal Update

02 September 24

Appendix 3Z - Mary Harney

×

Appendix 3Z - Mary Harney

02 September 24

Appendix 3Z - Phillip Lynch

×

Appendix 3Z - Phillip Lynch

02 September 24

Appendix 3X - Dr Daniel Tillett

×

Appendix 3X - Dr Daniel Tillett

02 September 24

Appendix 3X - Dr Serge Scrofani

×

Appendix 3X - Dr Serge Scrofani

29 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

27 August 24

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

27 August 24

Corporate Governance Statement

×

Corporate Governance Statement

27 August 24

Appendix 4G

×

Appendix 4G

22 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

15 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

09 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

06 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

01 August 24

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

30 July 24

Bisantrene Phase 2 AML Trial Successful Concludes

×

Bisantrene Phase 2 AML Trial Successful Concludes

25 July 24

Race to Present at TechKnow July Conference

×

Race to Present at TechKnow July Conference

RAC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.06 -0.08 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.06 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.0 15.6 -36.1 Lock Lock Lock
     PE X Lock Lock Lock Lock 22.0 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 24.3 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.07 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -85.5 -12.3 -29.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.1 -5.4 -3.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.23 0.16 0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.21 0.14 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 192.8 -33.1 -33.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 153 161 165 Lock Lock Lock
Basic m Lock Lock Lock Lock 153 161 165 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 13 18 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -80.9 -13.4 -38.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -77.4 -13.1 -37.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -13 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -3 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -10 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.7 11.4 -39.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 31 -1 5 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.2 -70.2 10.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 34 22 17 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 38 27 20 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -34 -22 -17 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 36 25 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 36 25 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 163.1 -29.4 -28.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -29.9 -37.3 -68.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.1 -42.2 -81.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -45.0 -32.2 -63.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -25.1 -34.6 -43.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.0 1.7 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -92.9 -84.4 -93.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 24.1 20.4 9.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 24.1 20.4 9.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 91.4 98.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -441.5 -924.8 -511.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -29.9 -37.3 -68.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 743.5 955.5 1,192.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -743.5 -955.5 -1,192.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Frequently Asked Questions

The current share price of Race Oncology Ltd. (RAC:ASX) is AU$1.59.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$2.09.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.64.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0.0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.